Mantle cell lymphoma: new treatments targeted to the biology.
Mantle cell lymphoma (MCL) represents a distinct lymphoma subtype. The prognosis of patients with MCL is the poorest among lymphoma patients and the response to conventional treatments is inadequate. New approaches targeted to the biology of MCL and the genetics underlying the disease are being studied. Monoclonal antibodies directed at molecules expressed on MCL cells are already used in the clinical setting. This article reviews the literature on these and other new possible treatment modalities.
Bertoni
Francesco
F
Department of Experimental Hematology, Bart and The London Queen Mary's School of Medicine and Dentistry, London, United Kingdom.
Ghielmini
Michele
M
Cavalli
Franco
F
Cotter
Finbarr E
FE
Zucca
Emanuele
E
D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000096:biosynthesis; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D017209:Apoptosis; D002986:Clinical Trials as Topic; D003546:Cysteine Endopeptidases; D006801:Humans; D020522:Lymphoma, Mantle-Cell / Q000473:pathology* / Q000628:therapy*; D008875:Middle Aged; D009097:Multienzyme Complexes / Q000037:antagonists & inhibitors; D046988:Proteasome Endopeptidase Complex; D000069283:Rituximab; D016896:Treatment Outcome; D019444:Vaccines, DNA
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D009097:Multienzyme Complexes; D019444:Vaccines, DNA; D000069283:Rituximab; C422802:ibritumomab tiuxetan; D003546:Cysteine Endopeptidases; D046988:Proteasome Endopeptidase Complex; C119496:tositumomab I-131